Diabetes drug shows promise against Parkinson’s disease

Diabetes drug shows promise against Parkinson’s disease

A new promising clinical trial has suggested that a drug that is normally used to control type-2 diabetes may also play a crucial role in halting the progression of Parkinson’s disease.

In the clinical trial involving 62 patients, researchers found that the medicine successfully halted the headway of the Parkinson’s disease. However, the medicine was not found efficient in preventing brain cells dying, which causes the devastating disease.

The team of researchers from the University College London (UCL) said it was excited at the results, but added that any long-term benefit of the drug remained uncertain and it needed more testing.

Professor Tom Foltynie, one of the researchers involved in the study, said, “There’s absolutely no doubt the most important unmet need in Parkinson's is a drug to slow down disease progression, it's unarguable.”

In Parkinson’s disease, the patient’s brain gets progressively damaged and the brain cells that are responsible for producing the dopamine hormone are lost. It gradually leads to tremors, difficulty in moving and eventually creates memory problems.

The researchers detailed the results of the study in the most recent edition of the journal Lancet.